An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease
Phase of Trial: Phase I/II
Latest Information Update: 07 Sep 2017
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Holdings (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kangstem Biotech
- 01 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2018.
- 01 Sep 2017 Planned primary completion date changed from 1 May 2017 to 1 Sep 2018.
- 10 Jun 2017 Biomarkers information updated